Nom i cognoms / Name and surname
Azucena Bardají, Eve Nakabembe, Kirsty Le Doare
Afiliació / Affiliation
Instituto de Salud Global Barcelona (ISGLOBAL); MU-JHU Care Limited (MU JHU), Uganda; City St George’s, University of London, United Kingdom
Programa de finançament europeu en que s’enmarca aquest projecte? / European funding programme in which this project is being carried out?
Other (EU support, FP7, H2020, etc.)
Títol del projecte / Project title
PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa (PROTECT)
Número del projecte / Project number
101145724
Breu explicació del projecte / Brief explanation of your project
Infections are one of the key causes of newborn deaths. Among them, Group B Streptococcus (GBS) is the leading cause of sepsis and bacterial meningitis in the first 90 days of life.
Fortunately, GBS vaccines for pregnant women, a powerful tool for fighting infections, are currently in development. Once vaccine trials are completed, these vaccines can stop preventable newborn deaths.
The PROTECT consortium is supporting medical sites in Kenya, Malawi, Mozambique, and Uganda to establish uniform pregnancy and infant health data collection processes. It is also establishing surveillance of GBS in newborns to determine incidence rates and measure the burden of disease. With better reporting systems, medical sites can participate in vaccine trials and monitor vaccine safety. At the same time, the consortium is working to understand the drivers of vaccine hesitancy and to develop culturally appropriate communication tools to facilitate engagement with vaccines.
Our end goal is to set up a network of sites that can monitor vaccine safety for current and future vaccines.
Enllaç a la pàgina web del projecte / Link to your project website
https://www.protect-network.org/
